AAFA’s Medical Scientific Council Shares Statement on Early Pfizer/BioNTech COVID-19 Vaccine Safety Questions for People with Allergies

“Recent media reports of reactions to the new Pfizer/BioNTech COVID-19 vaccine, first out of the U.K and now one report in the United States are stirring safety concerns for people with a history of serious allergies.

It’s important to remember that we still don’t have the full details regarding the specifics of any of these reported reactions. Allergists, the Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC) are all keeping an eye on these reported adverse events.

We’re in the early stages of COVID-19 vaccine rollout. It is common to see adverse vaccine reactions once wider distribution to the general public begins, even if none of these reactions were observed in clinical trials. Additional vaccines are in the pipeline so there will likely be more options if it is determined that one vaccine works better in certain populations than others. It’s important to let the science do its work, not the headlines. Anyone with concerns about allergy risk should consult with their doctor.” – Mitchell H. Grayson, MD; Chair of the Asthma and Allergy Foundation of America’s Medical Scientific Council

Dr. Grayson is Director of the Division of Allergy and Immunology and Professor of Pediatrics at Nationwide Children’s Hospital and The Ohio State University.

Press Contact:
Kafi Drexel Brown, Public Relations Director
Asthma and Allergy Foundation of America (AAFA)
Cellular: 202.974.1223
kbrown@aafa.org

For continued information and updated AAFA resources on COVID-19 vaccines: The COVID-19 Vaccine: What We Know So Far
About AAFA
Founded in 1953, AAFA is the oldest and largest non-profit patient organization dedicated to saving lives and reducing the burden of disease for people with asthma, allergies and related conditions through research, education, advocacy and support. AAFA offers extensive support for individuals and families affected by asthma and allergic diseases, such as food allergies and atopic dermatitis (eczema). Through its online patient support communities, network of local chapters and affiliated support groups, AAFA empowers patients and their families by providing practical, evidence-based information and community programs and services. AAFA is the only asthma and allergy patient advocacy group that is certified to meet the standards of excellence set by the National Health Council. For more information, visit www.aafa.org.